MetabolicFTPPFat-targeted pro-apoptotic peptide

Adipotide

Fat-vasculature-ablating peptide · animal proof-of-concept only · no completed human trial

Adipotide is a fascinating laboratory idea with essentially no human evidence behind it — and that gap is the most important thing to know. It is a two-part designed peptide: one end (a short sequence called CKGGRAKDC) homes to a protein, prohibitin, found on the blood vessels that feed white fat, and the other end is a 'kill switch' (a pro-apoptotic domain) that, once delivered, destroys the cell from the inside by wrecking its mitochondria. The net result in animals is that the blood supply to fat tissue is ablated and the fat depot shrinks. In mice (2004) and then in spontaneously obese rhesus monkeys (2011), this produced striking weight loss — about 11% body-weight loss in the monkeys over 28 days, with improved insulin sensitivity. That is the part people quote. What they usually leave out: adipotide has never completed a human efficacy trial. The only human study, a Phase 1 in men with obesity and metastatic prostate cancer, was terminated with just four patients enrolled and no results ever posted. And the monkey study documented a kidney safety signal — rising creatinine and mild, reversible renal tubular changes — which is widely cited as the reason development stalled. There is no validated human dose, no human safety database, and any grey-market use rests entirely on animal data. Net: a clever, mechanistically distinct concept that simply has not been shown to be safe or effective in people.

The short version

Adipotide is best understood as a 'guided missile' aimed at fat tissue. Fat depots, like any living tissue, need a blood supply. Adipotide is built in two halves: a targeting half that recognizes and sticks to a marker (a protein called prohibitin) on the blood vessels feeding white fat, and a destructive half that, once it gets inside those vessel cells, triggers them to self-destruct. Kill the blood supply, and the fat it was feeding dies back too. That is the whole concept.

In animals, it worked impressively. In obese monkeys, a 28-day course produced about 11% body-weight loss along with better insulin sensitivity and clear reductions in fat on imaging. Those numbers are real — and they are why adipotide has a reputation.

But here is the honest core of it. That reputation rests entirely on animals. Adipotide has never finished a human trial. The single human study ever started — in men who had both obesity and advanced prostate cancer — was stopped with only four people enrolled and never reported any results. On top of that, the monkey study found a kidney warning sign: markers of kidney stress rose during treatment (they recovered afterward in the study), and that renal signal is the reason most often given for why the drug never moved forward. There is no proven human dose and no human safety record. Anything sold or used outside a lab is running purely on animal data.

Molecular identity

Specs

PubChem CID: 163360068
Molecular formula: C₁₁₁H₂₀₆N₃₆O₂₈S₂
Molecular weight: 2557.2 g/mol
Monoisotopic mass: 2555.52 Da

Type: Chimeric peptidomimetic — a prohibitin-homing motif fused to a pro-apoptotic domainPMID 22072637
Construct: CKGGRAKDC-GG-D(KLAKLAK)₂ (homing motif + mitochondrial-disrupting payload)PMID 15133506; PMID 22072637
InChIKey: GZESIPHLGJDZRG-VCWDIOOSSA-NPubChem
Molecular target: Prohibitin (on white-adipose-tissue blood-vessel endothelium)PMID 15133506
Half-life: Not established — no validated human pharmacokineticsNot established
Regulatory status: Not FDA-approved; no completed human efficacy trial (development stalled on a renal safety signal)ClinicalTrials.gov NCT01262664
Human evidence: None completed — the only human trial (NCT01262664) was terminated at 4 enrolled with no resultsClinicalTrials.gov NCT01262664

Plain English

Mechanism

Adipotide is a chimeric (two-domain) peptide. The first domain is a short cyclic sequence, CKGGRAKDC, identified by a screening technique (in-vivo phage display) as a homing motif that binds prohibitin — a protein displayed on the inner surface of the blood vessels that supply white adipose tissue. This is the 'address label' that concentrates the molecule at fat-feeding vasculature rather than elsewhere.

The second domain, D(KLAKLAK)₂, is a pro-apoptotic peptide built from D-amino acids (a mirror-image form that resists breakdown). It is relatively inert outside cells, but once the homing domain delivers it into the target endothelial cells, it disrupts their mitochondrial membranes and triggers apoptosis — programmed cell death. The two halves are joined by a short glycine-glycine linker.

The downstream logic is indirect: adipotide does not dissolve fat directly. It kills the endothelial cells of the fat's blood supply, the vessels regress, and the now-underperfused white-fat tissue undergoes secondary involution. This vasculature-targeting approach is mechanistically distinct from appetite suppressants or metabolic drugs — and it is also the source of the central safety question, because prohibitin and apoptotic targeting are not unique to fat. (The targeting protein is confirmed as prohibitin; a sometimes-cited second target, annexin A2, is not confirmed from the primary studies and is not asserted here.)

Sources:PMID 15133506 PMID 22072637

Why people reach for it

Potential benefits

Adipotide is reached for almost entirely on the strength of one striking animal result — but it carries a serious safety signal and never finished a human trial. These are the things people cite, kept deliberately modest and honest.

A genuinely novel fat-loss mechanism — Its real distinction. Rather than suppressing appetite or boosting metabolism, Adipotide ablates the blood supply that feeds white fat — a mechanistically distinct concept that set it apart from every other weight-loss approach.
Striking weight loss in animals — The number people quote: in spontaneously obese rhesus monkeys a 28-day course produced roughly 11% body-weight loss — but this is an animal result, never reproduced in a completed human trial.
Metabolic improvement alongside the fat loss — In that primate study the weight loss came with improved insulin sensitivity and reduced abdominal fat on imaging — reported in monkeys, not established in people.
Targeted, not appetite-driven — Because it works on fat-tissue vasculature rather than the brain's appetite circuits, it drew interest as a non-stimulant, non-appetite route to fat loss — an interest that remains purely preclinical.

Sources:PMID 15133506 PMID 22072637 NCT01262664

What draws attention to Adipotide, drawn strictly from its animal proof-of-concept (mice and monkeys) — not proven human outcomes. Hard safety caveat: there is no completed human efficacy trial (the only one was terminated at 4 patients), no validated human dose, and the primate work documented a kidney-toxicity signal that stalled development. No medical claims.

Implied timing

Best time to dose

Implied best time

Anytime (consistent, short cycle)

There is no meaningful time-of-day for Adipotide — the only coherent timing message is consistency across a short, cautious course, set against the fact that its safety is not established.

Adipotide's mechanism is slow and structural — it ablates fat-feeding vasculature so the fat depot involutes over days, not an acute effect tied to a daily peak — so the hour of injection has no mechanistic basis to favor.
In the animal and trial work it was given once daily over a fixed 28-day course; consistency across that kind of short, defined cycle is the only timing principle that maps to how it was actually studied.
No human pharmacokinetics or half-life exists, so there is no measured duration of action to time around — and the more important framing is the renal safety signal and absence of a validated human dose, which dominate any timing question.

No study establishes an ideal time of day for Adipotide — there is no human dosing schedule at all, and its development stalled on a kidney-toxicity signal. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for Adipotide the only honest guidance is consistency over a short course, not a specific hour.

How to run it

Dosing & protocol

Adipotide was given by subcutaneous injection in every study — there is no oral form for a peptide that would be digested by the gut. The sections below give the animal/trial figures as a factual record, describe the route as it was used, explain why this is not a casual protocol, and provide the reconstitution math the calculator runs from. There is no validated human dose and no approved cycle: the only human trial was terminated at four patients with no results.

Animal and trial figures for reference only — not a dosing recommendation. Adipotide has zero completed human efficacy trials; the lone human trial (NCT01262664) was terminated at n=4 with no results; a nephrotoxicity signal emerged in the primate work; no dose has been validated as safe in humans.

Trial/animal dose — reference only, no validated human dose

The numbers below are the animal and trial-design figures that define what is known — not numbers to follow.

Primate study (Barnhart 2011):: Daily subcutaneous administration for 28 days in spontaneously obese rhesus monkeys — the only completed primate efficacy study. Dose was given as mg/kg (weight-based animal dosing); no human-equivalent figure was derived or validated. Result: ~10.6% body-weight loss, improved insulin resistance. Also documented: reversible rise in serum creatinine + mild renal tubular degeneration — the safety signal that defines adipotide's human-risk profile.
Human trial (NCT01262664):: A Phase 1 dose-escalation in men with obesity and metastatic prostate cancer used a low starting dose by subcutaneous injection over 28 days. The trial was terminated with only 4 patients enrolled before reaching any conclusion. No efficacy or safety result was ever posted. There is no human dose established.
No human-equivalent dose:: Body-surface scaling from primates to humans has not been validated for a molecule with a known kidney signal. Vendor-circulated human mg/kg values are extrapolations without any trial support.

Subcutaneous administration

Subcutaneous injection was the route in both the primate study and the human trial — it is the only route with any data for this compound.

Injection site:: Abdomen (keeping a few inches clear of the navel), the outer thigh, or the love-handle area. Rotate sites between administrations to avoid local irritation.
Why not oral:: Adipotide is a peptide — it would be broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection is the only viable delivery route.
Food and timing:: As a subcutaneous peptide, adipotide does not interact with food timing. This is not a clinically relevant consideration for this compound.

Why this is not a casual protocol

The renal/nephrotoxicity signal and the terminated human trial are not footnotes — they are the defining reality of adipotide's risk profile.

Kidney toxicity is intrinsic to the mechanism:: Adipotide kills cells by ablating the blood supply to fat tissue. The pro-apoptotic mechanism is not fat-selective: prohibitin is expressed in other tissues, including the kidney vasculature. The monkey study documented rising serum creatinine and mild renal tubular degeneration — markers of real kidney stress. The study called these reversible within its 28-day follow-up window, but that observation was in a short controlled animal study, not a human safety trial.
Human trial terminated — no safety floor established:: The lone human study (NCT01262664) was stopped at 4 enrolled patients before any dose was declared safe or effective. There is no Phase 1 dose-escalation readout, no MTD (maximum tolerated dose), and no human pharmacokinetic or safety dataset. Every use outside a formal research setting operates with no safety floor at all.
No dose, schedule, or cofactor protocol mitigates the mechanism:: The nephrotoxicity is not a deficiency-driven side effect. It is an on-mechanism consequence of how a pro-apoptotic, vasculature-targeting agent distributes in the body. There is no cofactor, hydration regimen, or dosing schedule that has been shown to protect the kidneys from this mechanism. The safest protocol is none.

Reconstitution at a glance

The on-page calculator runs this live. These are the mixing math figures only — not a dosing recommendation.

Mixing (placeholder):: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 1,000 mcg = 20 IU. Adjust the calculator inputs for any vial size — the math scales linearly.

Sources:PMID 22072637 NCT01262664

Substrate the signal needs

Nutritional cofactor precision

Three questions drive cofactor reasoning: what substrate does the action consume (SUPPLY), what does it amplify (AMPLIFY), and what does it mitigate (MITIGATE)? For adipotide, the MITIGATE question dominates and forecloses the others — because the nephrotoxicity signal that killed this program is intrinsic to the mechanism, and no cofactor offsets it.

Reasoned from adipotide's pro-apoptotic vasculature-targeting mechanism — not from an adipotide cofactor study (none exists). The honest headline: there is no nutrient protocol that makes a preclinical, kidney-toxic, human-untested agent safe to use. The safest combination is none.

What no cofactor can fix (the renal/nephrotoxicity signal)

The most important thing to understand about adipotide's cofactor picture is what is absent from it.

The mechanism is not nutritional — it is structural:: Adipotide causes kidney stress because its pro-apoptotic, vasculature-targeting mechanism does not spare the renal vasculature. Prohibitin is expressed in kidney endothelium as well as fat-tissue endothelium. Killing cell mitochondria in fat vasculature also exposes kidney vasculature to the same payload. No vitamin, mineral, antioxidant, or hydration regimen changes that geometry. Protecting the kidneys from adipotide is an engineering problem — selectivity of the targeting domain — not a dietary one.
Hydration does not make a nephrotoxic agent safe:: Good hydration reduces kidney load from waste products and supports glomerular filtration. It does not prevent direct pro-apoptotic toxicity to renal tubular cells. The distinction matters: the monkey study documented tubular degeneration — a structural injury to the cells that line the kidney tubules — not simply dehydration. No fluid intake counteracts direct tubular cell death.
Nephrotoxic compounds must be avoided:: If anyone were to use this molecule, the rational 'anti-cofactor' list is compounds that already stress kidneys: NSAIDs at regular doses (ibuprofen, naproxen), aminoglycoside antibiotics, high-dose contrast agents, and any other recognized nephrotoxin. Combining any of these with a peptide that documented rising creatinine and tubular degeneration in primates compounds an already-unacceptable risk profile.
Honest summary:: The cofactor question for adipotide has one honest answer: the safest cofactor protocol is to not use the molecule. This section exists because the SUPPLY question has a real answer (fat loss consumes protein and electrolytes) — but the MITIGATE answer forecloses the whole frame. No nutrition protocol resolves the kidney question, and that is the one that matters.

General fat-loss process basics (SUPPLY — not adipotide-specific)

Rapid fat loss from any cause places demands on the body that general nutrition can support. This does NOT offset the nephrotoxicity mechanism — it is the backdrop of any fast weight-loss process.

Protein to limit lean mass loss:: ~1.6–2.2 g protein per kg bodyweight per day under any significant caloric or fat-loss burden. Rapid fat loss from any mechanism carries a muscle-loss risk; adequate protein limits that. This is generic fat-loss physiology, not an adipotide cofactor finding.
Electrolytes:: Sodium, potassium, and magnesium. Relevant under any protocol that produces rapid weight loss — the same basic physiology applies. Does not interact with adipotide's mechanism.
What this does not do:: None of these nutrients address the kidneys, the vascular targeting, or the pro-apoptotic mechanism. The safe, legal, human-proven alternative to an untested kidney-toxic peptide is a genuine caloric deficit + adequate protein + resistance training — these do the real work without any of the risk.

Combinations + timing

Stacking notes + timing windows

Adipotide has no responsible recommended stack. It is a preclinical, pro-apoptotic, vasculature-targeting agent with a documented nephrotoxicity signal, a terminated human trial, and no validated human dose. The honest answer to 'what stacks well with adipotide?' is a caution map, not a protocol.

Combinations reasoned from mechanism — not studied head-to-head, and adipotide itself has no completed human trial. The safest combination is none. Treat this section as a safety-forward thought experiment.

Adipotide + any fat-loss agent — do not combine

Pairing another fat-loss or weight-management compound with adipotide does not produce complementary mechanisms — it compounds an already-unacceptable risk profile.

GLP-1 agonists (semaglutide, tirzepatide, [[semaglutide]]):: GLP-1 agonists suppress appetite and slow gastric emptying — a completely different mechanism from adipotide's vascular ablation. In theory these are non-overlapping levers. In practice, combining a well-characterized, clinically proven agent with an untested, kidney-toxic, human-trial-terminated peptide adds adipotide's risk to the GLP-1's benefit without any studied synergy. The correct framing is that GLP-1 agonists do the safe, proven work; adipotide adds unquantified nephrotoxic risk on top of it.
Other peptide fat-loss agents (AOD-9604, frag 176-191):: These target fat mobilization through different pathways (lipolysis signaling, not vascular ablation). Stacking them with adipotide does not address adipotide's kidney risk — it layers an uncharacterized multi-agent exposure onto an already-uncharacterized single-agent exposure. There is no studied combination. The compounded risk is entirely unknown.
The rule:: The nephrotoxicity signal in adipotide's primate study is a repeat-dosing, on-mechanism phenomenon. Any co-administration adds additional variables to an already-unresolved safety baseline. The safest combination is none. This is not a caveat on top of a recommended stack — it is the whole answer.

Sources:PMID 22072637 NCT01262664

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 5 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

The headline safety signal is renal. In the obese-monkey study, adipotide caused a dose-dependent rise in serum creatinine (a marker of kidney stress) and mild renal tubular degeneration on histology. The study described these changes as reversible within its 28-day recovery period, but this kidney signal is the most commonly cited reason adipotide development stalled. Dehydration and kidney changes are the recurring concern.

Beyond the kidney, there is essentially no human safety database — so every other risk is theoretical. Because the mechanism is targeted apoptosis at vasculature expressing prohibitin, and prohibitin is not exclusive to fat, off-target effects on other tissues' blood supply are a plausible but uncharacterized concern. The irreversible nature of cell killing also means errors in targeting would not be self-correcting.

The bottom line for safety is that adipotide's human risk profile is unknown. The one human trial was terminated before producing data, no validated dose exists, and the only documented toxicity — the renal signal — comes from animals. This is an experimental molecule, not a characterized drug.

Sources:PMID 22072637 NCT01262664

As reported in literature

Research dosing ranges

The table below makes the evidence boundary unmistakable: adipotide's weight-loss reputation is built on mouse and monkey studies, and the only human trial was terminated with no results. The doses shown are ANIMAL doses, given for context — there is no validated human dose. Route was subcutaneous.

Dose	Route	Model	Outcome	Sources:
Targeted ablation (mouse)	Subcutaneous	Mouse — Kolonin 2004 (origin study)	Targeted ablation of fat-vasculature reversed obesity — established the CKGGRAKDC/prohibitin concept; no human relevance for dose	PMID 15133506
Animal dose (mg/kg), 28 days	Subcutaneous, once daily	Spontaneously obese rhesus monkeys — Barnhart 2011 (n=10 treated, 5 control)	≈10.6% body-weight loss over 28 days, reduced abdominal fat, improved insulin resistance; reversible rise in serum creatinine + mild renal tubular degeneration	PMID 22072637
Low starting dose (escalation)	Subcutaneous, daily ×28 days	Human — Phase 1 in obesity + metastatic prostate cancer (NCT01262664)	TERMINATED with only 4 enrolled; NO results posted — no human efficacy or safety conclusion exists	NCT01262664

Quick answers

Frequently asked

Has adipotide been tested in humans?

Not in any completed trial. The only human study ever started — a Phase 1 in men with obesity and metastatic prostate cancer (NCT01262664) — was terminated with just four patients enrolled and never posted any results. All of adipotide's weight-loss evidence comes from mice and monkeys.

How does adipotide cause weight loss?

Indirectly. It is a two-part peptide: one end homes to a marker (prohibitin) on the blood vessels feeding white fat, and the other end triggers those vessel cells to self-destruct. Cutting off the blood supply causes the fat tissue to shrink. It does not directly burn or dissolve fat.

What were the animal results?

In spontaneously obese rhesus monkeys, a 28-day course produced about 11% body-weight loss with reduced abdominal fat and improved insulin sensitivity. The foundational mouse study showed targeted fat-vasculature ablation reversed obesity. These are genuine animal findings — but they have not been reproduced in any completed human trial.

Why did adipotide development stall?

The most commonly cited reason is a kidney safety signal seen in the monkey study — rising creatinine and mild renal tubular changes (reported as reversible in the study). Combined with the narrow margin inherent in a cell-killing mechanism, this renal toxicity is the usual explanation, and the lone human trial was terminated early without results.

Is there a known safe human dose?

No. There is no validated human dose and no human safety or pharmacokinetic data. The doses reported for adipotide are animal doses (milligram-per-kilogram, subcutaneous), and no human equivalent has been established. Any dosing protocol circulating outside research is unsupported.

Primary sources

References

PMID 15133506Kolonin et al., Nature Medicine 2004 — origin study: CKGGRAKDC homing peptide + prohibitin target; targeted ablation reverses obesity in mice
PMID 22072637Barnhart et al., Science Translational Medicine 2011 — adipotide in obese rhesus monkeys: ~10.6% weight loss, improved insulin resistance, reversible renal signal
NCT01262664ClinicalTrials.gov NCT01262664 — first-in-man Phase 1 in obesity + metastatic prostate cancer; TERMINATED, n=4 enrolled, no results posted
PubChem CID 163360068PubChem CID 163360068 — adipotide: C₁₁₁H₂₀₆N₃₆O₂₈S₂, MW 2557.2, InChIKey GZESIPHLGJDZRG-VCWDIOOSSA-N

Research use only · Not medical advice · Updated 2026-06-01